Trial Profile
Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jun 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Capecitabine
- Indications Biliary cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 03 Jun 2022 Status changed from active, no longer recruiting to completed.
- 02 Feb 2022 Planned primary completion date changed from 31 Jan 2022 to 1 Apr 2022.
- 09 Dec 2021 Status changed from recruiting to active, no longer recruiting.